Acute effect of L‐796568, a novel β3‐adrenergic receptor agonist, on energy expenditure in obese men

van Baak, Marleen A., Hul, Gabby B. J., Toubro, Søren, Astrup, Arne, Gottesdiener, Keith M., DeSmet, Marina, Saris, Wim H. M.·2002·Clinical Pharmacology & Therapeutics
DOI 10.1067/mcp.2002.122527

Cited by (109)

Items 101–109 of 109

  1. Obesity
    2006 · Wiley Handbook of Current and Emerging Drug Therapies
  2. References
    2011 · CRC Press eBooks
  3. BindingDB Entry 50039497: Combination of a Beta adrenoceptor modulator and a norepinephrine-serotonin uptake inhibitor for the treatment of obesity.
    BindingDB · 2013 · UC San Diego
  4. BindingDB Entry 50047058: Discovery of Vibegron: A Potent and Selectiveß3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.
    BindingDB · 2017 · UC San Diego
  5. BindingDB Entry 50044030: Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists.
    BindingDB · 2014 · UC San Diego
  6. BindingDB Entry 50035396: Potent and selective, sulfamide-based human beta 3-adrenergic receptor agonists.
    BindingDB · 2012 · UC San Diego
  7. BindingDB Entry 50013342: Cyclic amine sulfonamides as linkers in the design and synthesis of novel human beta(3) adrenergic receptor agonists.
    BindingDB · 2009 · UC San Diego
  8. BindingDB Entry 50018277: Potent benzimidazolone based human beta(3)-adrenergic receptor agonists.
    BindingDB · 2009 · UC San Diego
  9. BindingDB Entry 50021381: Potent oxindole based human beta3 adrenergic receptor agonists.
    BindingDB · 2009 · UC San Diego